IMMUNOHISTOCHEMISTRY, GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP)

The IHC – GFAP (Glial Fibrillary Acidic Protein) test is an advanced immunohistochemistry-based diagnostic assay used to detect GFAP protein expression in tissue samples. GFAP is an intermediate filament protein primarily found in astrocytes, which are supportive cells of the central nervous system.

This test is widely used in neuropathology to identify tumors and disorders involving glial cells, particularly astrocytic tumors such as astrocytoma and glioblastoma. GFAP is considered one of the most important markers for confirming glial cell origin in brain and spinal cord tumors.

Benefits of the Test

• Helps diagnose glial tumors of the brain and spinal cord
• Assists in identifying astrocytic differentiation
• Supports accurate classification of central nervous system tumors
• Differentiates glial tumors from metastatic cancers
• Improves treatment planning and prognosis evaluation

Why Doctors Recommend This Test

Doctors recommend the IHC GFAP test when there is suspicion of brain tumors or neurological tissue abnormalities. It is commonly used in:

• Suspected astrocytoma or glioblastoma
• Evaluation of brain mass lesions
• Differentiating primary brain tumors from metastatic tumors
• Classification of central nervous system neoplasms
• Neuropathology biopsy interpretation

GFAP is often used alongside markers such as S100, EMA, synaptophysin, OLIG2, and Ki-67 to ensure precise diagnosis and tumor grading.

Preparation Before Test

No special preparation is required for the patient. Important considerations:

• The test is performed on brain or nervous tissue biopsy samples
• No fasting or medication restrictions are needed
• Previous imaging reports (MRI/CT) assist in accurate interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen complexity and laboratory workload.

Who Should Take This Test

• Patients with suspected brain tumors
• Individuals with spinal cord lesions
• Cases requiring neuropathological tumor classification
• Patients undergoing CNS biopsy evaluation
• Oncology patients requiring confirmation of glial origin

The IHC GFAP test is a critical tool in modern neuropathology. It helps pathologists accurately identify glial tumors and distinguish them from other central nervous system lesions, ensuring timely diagnosis and effective treatment planning.